Shorter treatment plans for drug-resistant TB cheaper, more effective: ICMR

It assessed the cost-effectiveness of the shorter bedaquiline-based regimens -- BPaL (bedaquiline, pretomanid and linezolid) and BPaLM (with moxifloxacin) -- in comparison with the nine-to-11-month and the 18-to 20-month-long bedaquiline-containing treatment plans used under the National TB Elimination Programme (NTEP).